Home Medizin Die Kombination aus HPV und metabolischem Syndrom ist mit einem höheren Sterblichkeitsrisiko bei Frauen verbunden

Die Kombination aus HPV und metabolischem Syndrom ist mit einem höheren Sterblichkeitsrisiko bei Frauen verbunden

von NFI Redaktion

In a study recently published in the journal Plus One, researchers examined the relationships between human papillomavirus (HPV) and metabolic syndrome (MetS) as well as the effects of these comorbidities on the overall mortality risk of clinically diagnosed HPV and MetS in men and women. Using data from seven consecutive data collection cycles of the National Health and Nutrition Examination Survey (NHANES) in the United States, involving over 5,100 individuals aged 18-65 with an average follow-up period ranging from 3.5 to 30 years after the first HPV and MetS diagnosis, the study investigated the association between HPV, MetS, and overall mortality. Study: Relationship between human papillomaviruses, metabolic syndrome, and overall death; Analysis of the US NHANES 2003-2004 to 2015-2016. Image source: Kateryna Kon / Shutterstock

Data analysis revealed that while HPV (of any type) did not have a direct association with increased overall mortality, co-infections of HPV (particularly high-risk subtypes) and MetS significantly increased the overall mortality risk in women compared to the cohort without HPV or MetS samples. This study lays the groundwork for future research aiming to elucidate the temporal, vaccination status, age, and gender effects of HPV, paving the way for novel interventions against this increasingly prevalent disease.

Human papillomavirus (HPV) is an umbrella term for over 200 closely related virus strains responsible for the most common sexually transmitted infection worldwide. Some HPVs have been found to be carcinogenic, contributing to various malignancies. Metabolic syndrome (MetS) is a cluster of cardiovascular diseases, including obesity, hypertension, dyslipidemia, and insulin resistance. MetS has been associated with increased prevalence and persistence of HPV, but the cumulative effects and interactions between HPV and MetS remain unknown.

The aim of this study was to assess the combined effects of HPV and MetS on overall mortality risk in men and women. Data from NHANES were used, with participants aged 18-64 providing socio-demographic and medical history, nutrition questionnaires, and laboratory tests. Clinical diagnoses of HPV and MetS were verified, with HPV determined from vaginal, penile, and oral swabs and MetS from waist circumference, blood pressure, blood sugar, triglyceride or high-density lipoprotein cholesterol measurements. Cox proportional hazard ratios were calculated to evaluate the joint effects of HPV and MetS on overall mortality.

Of the 71,058 NHANES cohort participants, 5,101 met the study’s inclusion criteria and were included in the final analyses. Significant differences in HPV prevalence were observed between men and women, with variations in risk categories. Over the average follow-up period of 9.4 years, 240 all-cause deaths occurred, with higher mortality rates in the high-risk HPV group. Further research is needed to fully understand the implications of HPV, MetS, and their interactions on overall mortality.

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.